Herve Affagard

📻𝗜𝗔𝗖𝗛 𝗥𝗮𝗱𝗶𝗼: 𝗢𝗻 𝗔𝗶𝗿 𝗳𝗿𝗼𝗺 #EHA2025 𝘗𝘰𝘰𝘭𝘦𝘥 𝘍𝘦𝘤𝘢𝘭 𝘈𝘭𝘭𝘰𝘨𝘦𝘯𝘪𝘤 𝘔𝘪𝘤𝘳𝘰𝘣𝘪𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘧𝘰𝘳 𝘙𝘦𝘧𝘳𝘢𝘤𝘵𝘰𝘳𝘺 𝘎𝘢𝘴𝘵𝘳𝘰𝘪𝘯𝘵𝘦𝘴𝘵𝘪𝘯𝘢𝘭 𝘈𝘤𝘶𝘵𝘦 𝘎𝘳𝘢𝘧𝘵-𝘷𝘦𝘳𝘴𝘶𝘴-𝘏𝘰𝘴𝘵 𝘋𝘪𝘴𝘦𝘢𝘴𝘦 iach.org/iach-news-podc… @EHA_Hematology @Mohty_EBMT

Live at #EHA2025 - proud to see Prof. Mohty @Mohty_EBMT presenting promising data for GvHD patients treated with Xervyteg!

📄 [Press release] – MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸 Key highlights: ✅ The independent DSMB has recommended that the study proceed without modification. ✅ Favorable safety profile and tolerability for MaaT033, a standardized pooled donor-derived drug candidate in oral formulation. Upcoming milestones: ▪ Next DSMB unblinded interim analysis with mortality monitoring scheduled for Q3 2025 at the 120-patient mark. ▪ Routine DSMB review for ongoing safety also expected for Q3 2025. 👉Read the press release here: maatpharma.com/april-8-2025-m… #Hematology #Oncology #BloodCancer #Cancer #DSMB #Safety #Tolerability #Phase2 #Microbiome #Microbiota

📄[Communiqué de presse] – MaaT Pharma annonce le résultat positif de l’analyse intermédiaire de sécurité du DSMB pour l'essai clinique de Phase 2b en cours évaluant MaaT033 pour les patients recevant une allo-GCSH 🩸 Points clés : ✅ Le DSMB a recommandé la poursuite de l'essai sans modification. ✅ Profil de sécurité favorable et une bonne tolérance pour MaaT033, un candidat-médicament standardisé de forme orale développé à partir de plusieurs donneurs. Prochaines étapes : · Prochaine analyse intermédiaire après la levée d’aveugle par le DSMB prévue au troisième trimestre 2025, après l’inclusion du 120ème patient. · Evaluation de sécurité régulière du DSMB aussi attendue pour le troisième trimestre 2025. 👉Lire le communiqué de presse ici : maatpharma.com/fr/8-avril-202… #Oncologie #CancersDuSang #Cancer #DSMB #Sécurité #Tolérabilité #Phase2 #Hématologie #Microbiome #Microbiote

📰 MaaT Pharma in @LePoint! We’re proud to be featured in the special issue “Ces projets qui façonnent la santé du futur” (Shaping the future of healthcare), written by Valérie Peiffer and Raphaël Ruffier-Fossoul, highlighting our pioneering work in restoring gut microbiome functions to support patients with life-threatening conditions, especially in oncology. Newspaper available at newsstands or via this link: lepoint.fr/versions-numer…

📰 More Great Media Coverage for our positive safety update for MaaT033 in Phase 2b trial! We’re proud to see @InvestirFr Les Echos cover the DSMB’s favorable interim safety assessment in our ongoing study in allo-HSCT patients. 👉 Read the article here: investir.lesechos.fr/actu-des-valeu… 📰 Nouvelle belle couverture médiatique pour notre actualité sur MaaT033 ! Nous sommes fiers de voir @InvestirFr Les Echos relayer l’analyse intermédiaire de sécurité favorable menée par le DSMB dans le cadre de notre essai clinique de Phase 2b chez les patients recevant une allo-GCSH. 👉Lire l’article ici : investir.lesechos.fr/actu-des-valeu… #Microbiome #AlloHSCT #ClinicalTrials #MaaT033 #DSMB #Safety #Phase2

📰 #Media - We’re proud to be featured for the first time in Het Financieele Dagblad @FD_Nieuws, a leading Dutch financial daily newspaper, In an article highlighting the thriving life sciences ecosystem in Lyon, the piece includes our recent clinical milestones, our manufacturing capacities and our regulatory ambitions — all driven by our pioneering work in microbiome science. We're proud to be included alongside other key institutions and innovative companies helping to shape the future of life sciences: @sanofi @biomerieux @Boehringer @Lyonbiopole @OsivaxVaccines @WHO_Europe 👉 Read the article here: fd.nl/bedrijfsleven/… Thank you @OnlyLyon and Florent Gerbaud for the great opportunity. #Oncology #Biotech #ClinicalTrials #Innovation #Lyon

📄 [Communiqué de Presse] – MaaT Pharma annonce la mise à disposition du Document d’Enregistrement Universel (DEU) 2024 👉 Accéder au document : #inforegle" target="_blank" rel="nofollow noopener">maatpharma.com/fr/investisseu…

📄 [Press release] – MaaT Pharma Announces the Availability of its 2024 Universal Registration Document (URD) 👉 Access the document: #inforegle" target="_blank" rel="nofollow noopener">maatpharma.com/investors/#inf…

📢 [#EVENT] - We are proud to share that Bastien Laperrousaz, our Director of Preclinical Development, will be presenting at the American Association for Cancer Research @AACR Annual Meeting 2025. He will comment on promising preclinical data for MaaT034, our synthetic microbiome therapy, designed to improve patients’ responses to immunotherapies. 📅 April 25-30, 2025 📍 Chicago, Illinois Stay tuned for more on how microbiome modulation could support the future of cancer care. #AACR2025 #Immunotherapies #Microbiome #Cancer #Oncology #Innovation #Research #Preclinical

@EmmanuelMacron @EmmanuelMacron - En tant que "patron" je suggère aussi que l'on mette beaucoup d'enegergie pour créer un environnement business friendly en Europe (Reglementation, marchés boursiers, etc...).

On ne corrige pas des déséquilibres commerciaux en mettant des tarifs douaniers.

💡 [#WorldCancerDay 2025] - There’s never been a more exciting time in #microbiome #research, especially in #oncology. We’re proud that our ARES trial is contributing to the field, and to a potential breakthrough treatment. Learn more from Professor @Mohty_EBMT on what it could mean for #patients. #Oncology #Hematology #aGvHD #Cancer

📰 - MaaT Pharma in Bloomberg @business - We’re proud to see our work featured in Bloomberg, spotlighting the potential of microbiome therapy in cancer care. The article and film share the inspiring patient’s story, who overcame aGvHD, a life-threatening complication after a stem-cell transplant, and includes a testimonial from Dr. Loschi, who treated her through the Early Access Program. Thank you to Jason Gale @jwgale for writting avout the potential of microbiome-based therapies beyond infectious diseases. 🔗 Read the full Bloomberg article: bloomberg.com/news/articles/… 🔗 Watch the video on Bloomberg Originals: youtube.com/watch?v=P8pd0T… #Bloomberg #MicrobiomeTherapy #CancerCareInnovation #GVHD #Microbiome #Hematology #Oncology #JPM2025

.@MaaT_Pharma 's MaaT013 has the potential to be the first approved third-line treatment option & transform the survival outcomes and redefine long-term prospects for approximately 3,000 third-line GI-aGvHD patients per year in the U.S., Canada & Europe. bit.ly/3Wd57jk

📄[Press release] – MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT🩸 maatpharma.com/january-21-202… #Microbiome #BloodCancer #Cancer #DSMB #Safety #Tolerability #Phase2

📄[Communiqué de presse] – MaaT Pharma annonce le résultat positif du deuxième DSMB pour l'essai clinique de Phase 2b en cours évaluant MaaT033 pour les patients recevant une allo-GCSH 🩸 👉maatpharma.com/fr/21-janvier-… #Microbiote #CancersDuSang #Cancer #DSMB #Sécurité #Tolérabilité #Phase2

Steep streets of #SanFrancisco are like the entrepreneur's journey: full of uphill climbs, unexpected turns, and rewarding views at the top. No exception during #JPM2025, every climb leads to a breathtaking view. 🚋✨ #Entrepreneurship #GoodVibes @MaaT_Pharma

@MaaT_Pharma @herve @FierceBiotech @RebeccaEFriend Thank you @RebeccaEFriend

🎥 Behind the scenes in San Francisco! MaaT Pharma’s CEO, @Herve Affagard @HAffagard sat down today with @FierceBiotech 's Rebecca Willumson @RebeccaEFriend during #JPM2025 for an exclusive interview. They discussed our exciting Phase 3 ARES data announcement and what’s ahead for MaaT Pharma in 2025. Stay tuned—the full video will be shared in the coming weeks. #Cancer #Oncology #MicrobiomeInnovation #Biotech #HealthcareTransformation